Categories
Tag: HCC
Adding Pembrolizumab to Lenvatinib Shows ‘Encouraging’ DOR in Advanced HCC
Adding Pembrolizumab to Lenvatinib Shows ‘Encouraging’ DOR in Advanced HCC Compared with lenvatinib (Lenvima) plus placebo, adding pembrolizumab (Keytruda) to lenvatinib resulted in consistent overall (OS) and progression-free survival (PFS) outcomes previously found in the phase 3 LEAP-002 trial (NCT03713593) of patients with advanced hepatocellular carcinoma (HCC). However, 35% of…
Comprehensive Review of Small Interfering RNAs (siRNAs)
Introduction Cancer, also called malignancy, is a group of diseases caused by the rapid multiplication and spread of malignant cells.1,2 According to statistics from the National Cancer Center, more than 100 types of cancer have been identified.3 The ability of malignant tumor cells to metastasize via the blood-lymphatic system and…
2023-12-08 | NYSE:MRK | Press Release
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, did not meet its dual primary endpoints of overall…
HER2 low expression breast cancer subtyping and their correlation with prognosis and immune landscape based on the histone modification related genes
Barzaman, K. et al. Breast cancer: Biology, biomarkers, and treatments. Int. Immunopharmacol. 84, 106535 (2020). Article CAS PubMed Google Scholar Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73(1), 17–48 (2023). Article PubMed Google Scholar Mueller, C., Haymond, A.,…
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)
PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb Company Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary Endpoint Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -8HW trial evaluating…
Irreversible electroporation of hepatocellular carcinoma and colorectal cancer liver metastases : A nationwide multicenter study with short- and long-term follow-up
@article{4a354106-4e26-4c4c-8bce-d55a1fcd19cc, abstract = {{<p>Introduction: A nationwide multicenter study was performed to examine short- and long-term effects of irreversible electroporation (IRE) for hepatocellular carcinoma (HCC) and colorectal cancer liver metastases (CRCLM). IRE is an alternative method when thermal ablation is contraindicated because of risk for serious thermal complications. Methods: All consecutive…
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic…
Application based on results from the Phase 3 CheckMate -901 trial showing significant survival improvement vs. standard-of-care gemcitabine plus cisplatin in cisplatin-eligible patients with untreated, unresectable or metastatic urothelial carcinoma If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the U.S. The…
error when installing gistic2 using conda
error when installing gistic2 using conda 0 Dear all, How to fix the error when using conda to install the gistic2? I already use conda to create a new directory/environment, and then conda install -hcc gistic2 as the conda website shows anaconda.org/HCC/gistic2 conda install -c hcc gistic2 Collecting package metadata…
Targeting the epigenome to reinvigorate T cells for cancer immunotherapy | Military Medical Research
Tsui C, Kretschmer L, Rapelius S, Gabriel SS, Chisanga D, Knöpper K, et al. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. Nature. 2022;609(7926):354–60. Article CAS PubMed PubMed Central Google Scholar Zhu L, Zhou X, Gu M, Kim J, Li Y, Ko CJ, et al. Dapl1 controls NFATc2…
Cadonilimab/Chemotherapy Meets Primary End Point in Phase 3 AK104-303 Trial
Cadonilimab/Chemotherapy Meets Primary End Point in Phase 3 AK104-303 Trial Findings from the phase 3 AK104-303 trial (NCT04982237) suggest that patients with recurrent or metastatic cervical cancer may derive a progression-free survival (PFS) benefit with frontline cadonilimab (AK104) plus platinum-based chemotherapy—with or without bevacizumab (Avastin). Data from the prespecified interim…
Identification of differentially expressed circRNAs in prostate cancer of different clinical stages by RNA sequencing
CircRNAs are widely found in eukaryotes and are a class of abundantly expressed, highly tissue-specific, and stable non-coding RNAs that have an essential role in regulating gene expression12. The abnormal expression of circRNAs has been reported in esophageal squamous cell carcinoma13, breast carcinoma14, gastric cancer15, and hepatocellular carcinoma16, which are…
EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma
The objective of this study was to evaluate a composite biomarker of EpCAM-positive circulating tumor cells and serum AFP to identify patients at high risk of early recurrence within 2 years after liver resection. While AFP is elevated in less than half of patients with HCC, it is associated with tumor…
H101 for cervical cancer | DDDT
Introduction Patients with persistent, recurrent, or metastatic (P/R/M) cervical carcinoma respond poorly to treatment despite the best available therapeutic regimens, with a 5-year survival of 17%.1 Most of them are heavily pretreated with chemotherapy and/or radiotherapy, and many patients experience complications related to treatment or advanced disease, which exclude them…
AstraZeneca shares positive phase 3 results for Imfinzi combination in liver cancer
AstraZeneca (AZ) has shared positive results from a late-stage study of its immunotherapy Imfinzi (durvalumab) when used as part of a combination treatment in a subset of patients with hepatocellular carcinoma (HCC), the most common type of liver cancer. The phase 3 EMERALD-1 trial has been evaluating Imfinzi plus transarterial…
Durvalumab/Bevacizumab Yields Notable PFS Improvement in Liver Cancer
“These results for durvalumab plus bevacizumab have the potential to reshape the treatment of this complex disease with a poor prognosis by showing for the first time that adding an immunotherapy combination to TACE significantly improves [PFS],” according to Riccardo Lencioni, MD, FSIR, EBIR. Patients with hepatocellular carcinoma (HCC) who…
Establishment of a prognostic signature based on fatty acid metabolism genes in HCC associated with hepatitis B | BMC Gastroenterology
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. Article PubMed Google Scholar Chen W, Zheng R, Baade PD, Zhang S, Zeng H,…
Gholam Explores the Phase 3 RATIONALE-301 Study of Sorafenib in HCC
Pierre Gholam, MD, professor at Case Western Reserve University School of Medicine in Cleveland, Ohio, discusses the phase 3 RATIONALE-301 (NCT03412773) study of frontline tislelizumab (BGB-A317) vs sorafenib (Nexavar) for patients with hepatocellular carcinoma (HCC). The global, phase 3 RATIONALE-301 trial randomized 674 patients to receive tislelizumab, an IgG4 anti-PD-1…
Circulating cell-free DNA fragmentation is a stepwise and conserved process linked to apoptosis | BMC Biology
DNA fragmentation of apoptotic cells is a two-step process which gives rise to major and minor peaks at different places DNA ladder formation is the most well-known characteristic of apoptosis. Since the 1990s, the HL60 cell line has been regarded as an ideal model for studying cell apoptosis [15]. We therefore took advantage of…
Durvalumab Plus TACE and Bevacizumab Significantly Improves PFS in Select HCC
Riccardo Lencioni, MD, FSIR, EBIR Durvalumab (Imfinzi) plus concurrent transarterial chemoembolization (TACE) followed by durvalumab with bevacizumab (Avastin) resulted in a significant improvement in progression-free survival (PFS) over TACE alone in patients with hepatocellular carcinoma (HCC) who are eligible for embolization, meeting the primary end point of the phase 3…
Durvalumab/Bevacizumab Shows Clinically Meaningful PFS Improvement in HCC
3d illustration of human body liver: © PIC4U – stock.adobe.com The combination of durvalumab (Imfinzi) with transarterial chemoembolization (TACE) and bevacizumab (Avastin) led to a statistically significant and clinically meaningful improvement in progression-free survival in patients with hepatocellular carcinoma (HCC) eligible for embolization, meeting the primary end point of the…
Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network | Genome Medicine
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. Article PubMed Google Scholar Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E,…
Final Highlights from the 2023 ASHG Annual Meeting
When it comes to covering a conference as large as the annual meeting of the American Society of Human Genetics (ASHG), one of the biggest challenges is capturing the full breadth of content in a handful of stories. Last week, GEN’s editorial team published three special edition newsletters covering the…
Will There Be A Nobel Prize For AI?
Alfred Nobel, by JONATHAN NACKSTRAND/AFP via Getty Images AFP via Getty Images The Nobel Awards Season just ended, with the “Oscars of Science” awarded to some of the world’s brightest minds. The entire science world was watching, and just like with the Oscars, there was an element of suspense, drama,…
CRISPR-Cas9 gene editing in liver disease
Introduction to CRISPR-Cas9 Gene EditingLiver disease: the need for innovative treatmentsCRISPR-Cas9 applications in liver diseasePrecision medicine and personalized treatmentFuture prospects and research directionsrefer to further reading CRISPR-Cas9 gene editing has great potential in the field of precision medicine for liver diseases. This innovative technology allows researchers to precisely modify genes…
Harnessing the Power of CRISPR-Cas9 Gene Editing for Liver Diseases
Liver diseases continue to pose significant challenges to global health, necessitating the exploration of innovative treatment approaches. One technology that shows immense promise is CRISPR-Cas9 gene editing, which enables precise modifications to genes associated with liver conditions, offering hope for targeted therapies. CRISPR-Cas9 gene editing, a revolutionary technique in genetic…
CRISPR Therapeutics : SITC 2023 (GPC3) -October 31, 2023 at 09:19 am EDT
Title: Development of allogeneic, potency-edited,anti-GPC3CAR-T cells for the treatment of hepatocellular carcinoma Authors: Daniel Henderson, Minh Thu Pham, Dan Li, Mitchell Ho, Jason Sagert Background: Glypican-3 (GPC3) is an oncofetal heparan sulfate proteoglycan and is associated with cell proliferation, differentiation, and mobility through Wnt, Yap, and other signaling pathways. GPC3…
Diet-induced rewiring of the Wnt gene regulatory network connects aberrant splicing to fatty liver and liver cancer in DIAMOND mice
DIAMOND mice develop HCC in the context of obesity and insulin resistance To investigate in depth the genome-wide transcriptional and epigenetic changes that occur during development of MAFLD and obesity-related hepatocellular carcinoma (HCC), we performed RNA-sequencing (RNA-seq) and Chromatin ImmunoPrecipitation-sequencing (ChIP-seq) of liver tumours (HCC) and liver control tissue (FL)…
HOXC-AS3 as an Oncological Biomarker and Therapeutic Target
1Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330008, People’s Republic of China; 2Department of General Surgery, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, Jiangxi, 332007, People’s Republic of China; 3Queen Mary School, Nanchang University, Nanchang, Jiangxi, 330038, People’s Republic of China Correspondence: Hongliang Luo,…
Investigating chronic inflammation’s link to cancer
In most cases, chronic inflammation is known to lead to cancer, however, the mechanisms behind this are not fully understood. Preclinical models in immuno-oncology are the first step towards a better understanding of cancer mechanisms, improved treatments and prevention of cancer caused by inflammation. Inflammation is the immune system’s natural…
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
ALAMEDA, Calif.–(BUSINESS WIRE)– Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET) and a second cohort of patients…
Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Antibodies
Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma Details Category: Antibodies Published on Thursday, 19 October 2023 13:34 Hits: 279 Subcutaneous nivolumab demonstrates noninferior pharmacokinetics (co-primary endpoints) and objective response rate (key secondary endpoint) compared…
Characteristics, Biogenesis and Functions of CircRNAs
Circular RNA (CircRNA), a single-stranded closed-loop RNA that lacks terminal 5′ caps and 3′ poly (A) tails, is more stable than linear RNA. CircRNA was first discovered in plant-infected viroids and was later observed in eukaryotes, although it was not produced via the back-splicing mechanism. 1. Characteristics Circular RNA (CircRNA),…
Pseudogene MAPK6P4-encoded functional peptide promotes glioblastoma vasculogenic mimicry development
Gusyatiner, O. & Hegi, M. E. Glioma epigenetics: from subclassification to novel treatment options. Semin. Cancer Biol. 51, 50–58 (2018). Article PubMed Google Scholar Kunnakkat, S. & Narayana, A. Bevacizumab in the treatment of high-grade gliomas: an overview. Angiogenesis 14, 423–430 (2011). Article PubMed Google Scholar Luo, Q. et al….
MUSC College of Health Professions hiring UNIV – Research Specialist III- Bioinformatician – Department of Neuroscience in Charleston, South Carolina, United States
Job Description SummaryThe brand-new MUSC Bioinformatics Core (BioCM) is seeking a superb bioinformatician to develop scientific tools for single cell multiomics and other next-generation sequencing methods. Under the supervision and guidance of BioCM staff and Dr. Stefano Berto, the bioinformatician will contribute to NGS analysis projects, and they will work…
LINC01343 targets miR-526b-5p to facilitate the development of hepatocellular carcinoma by upregulating ROBO1
Tissue samples All the enrolled patients provided written informed consent. Patients who had undergone chemotherapy or radiotherapy before surgery were excluded from the study. Surgical procedures were performed to obtain 40 pairs of HCC tumor and adjacent non-tumor tissue specimens from patients admitted to the First Affiliated Hospital of Chengdu…
Tislelizumab Could Be a First-Line Treatment for HCC
3D illustration of human liver: ©PIC4U – stock.adobe.com Tislelizumab (Tevimbra), an anti-PD-1 monoclonal antibody, demonstrated overall survival (OS) improvements vs sorafenib (Nexavar) in patients with unresectable hepatocellular carcinoma (HCC), according to a study published in JAMA Oncology.1 In the phase 3 RATIONALE-301 trial (NCT03412773), the median OS was 15.9 (95%…
Lenvatinib, toripalimab plus FOLFOX chemotherapy in hepatocellular carcinoma patients with extrahepatic metastasis: A biomolecular exploratory, phase II trial (LTSC) | Clinical Cancer Research
Purpose: To investigate the efficacy, safety, and biomarkers of systemic chemotherapy with oxaliplatin, leucovorin and fluorouracil (FOLFOX) in combination with lenvatinib and toripalimab as the first-line treatment for advanced hepatocellular carcinoma (HCC) with extrahepatic metastasis. Patients and Methods: In this biomolecular exploratory, phase II trial, eligible patients underwent the triple…
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
Tempest Therapeutics Webcasted Conference Call on Wednesday, October 11, 2023 at 8:30 a.m. ET BRISBANE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the company plans to report new and…
G. lucidum triterpenes restores intestinal flora balance in non-hepatitis B virus-related hepatocellular carcinoma: evidence of 16S rRNA sequencing and network pharmacology analysis
. 2023 Sep 18:14:1197418. doi: 10.3389/fphar.2023.1197418. eCollection 2023. Affiliations Expand Affiliation 1 Chongqing Three Gorges Medical College, Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing, China. Free PMC article Item in Clipboard Wei Xiong et al. Front Pharmacol. 2023. Free PMC article…
The Therapeutic Effects of MUC1-C shRNA@Fe3O4 Magnetic Nanoparticles i
Introduction Breast cancer (BC) is a malignant tumor originating from the epithelial tissue of the breast and is the most common malignancy in women.1 It is estimated that by 2040, there will be 3,000,000 new cases of BC and 100,000 deaths worldwide. Triple-negative breast cancer (TNBC), which accounts for 15–20%…
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology
Key Points Question How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings In this phase 3 randomized clinical trial of 674 patients with HCC, tislelizumab demonstrated overall survival noninferiority compared with sorafenib, with numerically…
Study of some potential biomarkers in Egyptian hepatitis C virus patients in relation to liver disease progression and HCC | BMC Cancer
Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021;45(3):101596. Article PubMed Google Scholar Leumi S, El Kassas M, Zhong J. Hepatitis C virus genotype 4: a poorly characterized endemic genotype. J Med Virol. 2021;93(11):6079–88. Article CAS PubMed Google Scholar El Kassas M, Elbaz T, Elsharkawy A,…
r – in ggplot2 can you assign the aesthetic ‘shape’ to more than one variable?
I have an ordination plot and there are four environmental parameters I want to overlay. I have used the aesthetics: shape, colour and size for three of the variables and for the fourth i want the shapes to either be filled in or not filled in. I have attached a…
C2.CLIN gene sets listing – MSigDB [Broad Insititute]
C2:CLIN:0007 PANCREAS_CHR8_AGUIRRE HG_U133A Human Kate Stafford C2:CLIN:0030 L1_GR_G1 HG_U95Av2 Human Yujin Hoshida C2:CLIN:0006 PANCREAS_CHR7_AGUIRRE HG_U133A Human Kate Stafford C2:CLIN:0029 L0_SM_L1 HG_U95Av2 Human Yujin Hoshida C2:CLIN:0035 G2_SM_G3 HG_U95Av2 Human Yujin Hoshida C2:CLIN:0016 ESC_UP_BHATTACHARYA Gene_Symbol Human Kate Stafford C2:CLIN:0015 IL6_BROCKE HG_U95Av2 Human Kate Stafford C2:CLIN:0014 BCELL_ASTIER HG_U95Av2 Human Kate Stafford C2:CLIN:0031 L1_SM_G1…
Subclustering of intergated cells from scRNA-seq data
Subclustering of intergated cells from scRNA-seq data 1 I used SCTnormalization and Seurat integration to integrate 3 scRNA-seq datasets. After manual annotation using RNA assay, I have one particular cluster of cells with overexpressed different T cells markers. So, to find heterogeneity of T cells I subclustered that particular cluster:…
study identifies interaction between estrogen receptor and genetic variant in women
In a recent article published in Nature Medicine, researchers pursued evidence of whether the interaction between the patatin-like phospholipase domain-containing 3 (PNPLA3) p.I148M variant and the female sex at the genetic and molecular level explains why premenopausal women remain protected against fatty liver disease (FLD) while a rapidly progressive disease ensues in…
What Will Be the Next Frontline Therapy for HCC?
Richard S. Finn, MD, professor of Medicine at the Geffen School of Medicine at UCLA in the Department of Medicine, Division of Hematology/Oncology, discusses the next potential regimen to emerge for the frontline treatment of hepatocellular carcinoma (HCC). In early 2023, Finn presented findings from the SKYSCRAPER-14/IMbrave152 study of the…
ncRNA | Free Full-Text | The Intergenic Type lncRNA (LINC RNA) Faces in Cancer with In Silico Scope and a Directed Lens to LINC00511: A Step toward ncRNA Precision
CRC Upregulated 153-5p HIF-1 activates LINC00511, targeting HIF-1’s 3-UTR and +ve feedback loop [78] Oncogene Human CRC tissues vs. paired adjacent non-tumor and CRC cell lines HT29, LOVO, SW620, SW480 vs. normal colon epithelial FHC cell line and athymic BALB/c nude mice for implantation – HNF4 promotes LINC00511 transcription, interaction…
Induced Pluripotent Stem Cells (iPSCs) in the Modeling of Hepatitis C Virus Infection
Title:Induced Pluripotent Stem Cells (iPSCs) in the Modeling of Hepatitis C Virus Infection Volume: 10 Issue: 3 Author(s): Lin Cheng, Yong Zhang, Yuemin Nan and Liang Qiao Affiliation: Keywords: Disease modeling, hepatitis C virus, hepatocellular carcinoma, induced pluripotent stem cells, iPSCs, liver transplantation. Abstract: The development of induced pluripotent stem…
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo
PRINCETON, N.J.–(BUSINESS WIRE)– Bristol-Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -77T trial met its primary endpoint of improved event-free survival (EFS) as assessed by Blinded Independent Central Review (BICR) in patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). In a prespecified interim analysis,…
Combination of HBV Immunotherapy with shRNA
DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE to register or log in. AD1208686 Combination of HBV Immunotherapy with shRNA – Mediated PD-1/PDL Checkpoint Inhibition for Treatment of Chronic HBV 2023-10-01 More…
DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab
Tissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma (HCC) or hepatocholangiocarcinoma (H-CCK) following disease progression on frontline atezolizumab (Tecentriq) and bevacizumab (Avastin) to targeted therapy or another TKI based on identified genomic alterations, according to retrospective findings from a single-center study presented at the 2023…
OSE Immunotherapeutics announces: positive ph
Nantes, France – September 11, 2023, 6:00pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the peer-reviewed publication in Annals of Oncology* of the randomized Phase 3 clinical trial (Atalante-1) on T-cell epitope cancer vaccine Tedopi® in HLA-A2 positive patients with advanced or metastatic NSCLC in monotherapy…
New Developments in Image-Guided Percutaneous Irreversible Electroporation of Solid Tumors
Ruarus AH, Vroomen LGPH, Puijk RS, Scheffer HJ, Zonderhuis BM, Kazemier G, van den Tol MP, Berger FH, Meijerink MR. Irreversible Electroporation in Hepatopancreaticobiliary Tumours. Can Assoc Radiol J. 2018;69(1):38–50. doi.org/10.1016/j.carj.2017.10.005. Article CAS PubMed Google Scholar Zhang N, Li Z, Han X, Zhu Z, Li Z, Zhao Y, Liu Z,…
Tempest to Present at the H.C. Wainwright 25th Annual
BRISBANE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that Sam Whiting, M.D., Ph.D., chief medical officer of Tempest, will present at the H.C. Wainwright 25th Annual Global Investment Conference….
Geneos Therapeutics’ Groundbreaking Cancer Vaccine Trial Yields Remarkable Results: Complete Response Achieved in 8 out of 34 Patients with Advanced Liver Cancer
PLYMOUTH MEETING, PA — Geneos Therapeutics, a clinical-stage biotherapeutics company, recenlty announced updated data from GT-30, an ongoing single-arm open-label multi-center Phase 1b/2a study in second-line advanced hepatocellular carcinoma (HCC). Previously, Geneos reported three patients to have achieved a complete response (CR) and a fourth patient to be cancer-free, whose…
Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-010 Trial of KEYTRUDA pus LENVIMA
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided an update on the Phase 3 LEAP-010 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, as a first-line treatment for patients…
Metabolites | Free Full-Text | Targeted Metabolomics Analysis of Individuals Carrying the ANGPTL8 R59W Variant
The role of ANGPTL8 in metabolizing lipids and glucose and in metabolic disorders and inflammation is widely recognized [7,8,9,27,44,45,46]. The rs2278426, while a missense (R59W) variant in ANGPTL8, is located in the intron in the DOCK6 gene. The variant downregulates CTC-510F12.4 (a novel transcript) in whole blood, upregulates DOCK6 in…
Personalized Neoantigen Vaccine Induces Continued Responses in Pretreated, Advanced HCC
Ed Gane, MBChB, MD, FRACP, MNZM Intradermal injection with GNOS-PV02 plus plasmid-encoded interleukin-12 (PTCV) followed by electroporation elicited complete molecular response (CMR) detected via circulating tumor DNA (ctDNA) in 4 additional patients as second-line therapy in patients with advanced hepatocellular carcinoma (HCC), according to updated data from the open-label, multi-arm…
Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response
–By RECIST1.1, Three Complete Responses and Seven Durable Partial Responses Achieved to Date– –Three of the Seven Patients With Durable Partial Responses, and One With Stable Disease, Have Now Achieved Complete Molecular Response By Ultrasensitive ctDNA Analysis– –No Serious Adverse Events Related…
Exelixis and Ipsen Announce Positive Results from Phase 3
– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer – A trend toward improvement in overall survival was observed at first interim analysis – Findings will…
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
FDA encouraged the Company to enroll adolescent patients due to Piclidenoson’s good safety profile There is an unmet need for safe, convenient, and effective drugs to treat chronic plaque psoriasis in the adolescents PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline…
What is the next step in preventative therapi
image: In a chronic inflammatory context, epigenetic changes occur in LPCs: (1) through a sustained stimulation by cytokines that either promotes dedifferentiation and transformation of LPCs to CSCs (IL-17, TNF-α and IL-6), or in contrast avoiding their transformation (IFN-γ, IL-27); (2) by hosting small non-coding RNAs transferred by exosomes coming from…
Gene Expression Market to Reach USD 32.23 Billion by 2032; Rising Investments in Research and Development across Genomics & Biotechnology Sectors to Propel Growth: The Brainy Insights
The continuous advancement of cutting-edge solutions is expected to create substantial growth prospects throughout the forecast period. North America region emerged as the most prominent global Gene Expression market, with a 46.58% market revenue share in 2022. Newark, Aug. 15, 2023 (GLOBE NEWSWIRE) — The Brainy Insights estimates that the…
Gene Expression Market to Reach USD 32.23 Billion by 2032;
Newark, Aug. 15, 2023 (GLOBE NEWSWIRE) — The Brainy Insights estimates that the USD 12.28 billion in 2022 global gene expression market will reach USD 32.23 billion by 2032. Single-cell gene expression analysis has gained tremendous momentum in recent years. Advancements in technologies like single-cell RNA sequencing (scRNA-seq) offer the opportunity…
Cancers | Free Full-Text | CPSF3 Promotes Pre-mRNA Splicing and Prevents CircRNA Cyclization in Hepatocellular Carcinoma
The real effect of CPSF3 on circRNA expression in HCC cells was tested by analyzing the total RNA fractions obtained from CPSF3-KO HepG2 cells, CPSF3-OE Bel7404 cells, and negative control cells using high-throughput sequencing (Supplementary Files S7 and S8). The data obtained showed that CPSF3-KO cells had more types and…
Tempest Reports Second Quarter 2023 Financial Results and
BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2023 and provided a corporate update. “2023 continues to be a productive and…
PROs Represent a Vital Aspect in Design of GI Cancer Clinical Trials
Incorporating patient-reported outcomes (PROs) as a measurement of success in clinical trials, supplementary to measuring adverse effects (AEs), continues to be an area of great interest, across the gastrointestinal (GI) cancer landscape, and as clinical trials continue to evolve, it remains important to make sure that the patient’s voice is…
Top 5 Use Cases of AlphaFold in Life Sciences
Life sciences have undergone a radical change as a result of AI-powered protein model prediction. In 2022, protein folding models with Google DeepMind’s AlphaFold paper being the most-cited paper of the year. It has been two years since the London-based subsidiary of Alphabet, Google DeepMind, delivered the revolutionary answer to…
Elevar Therapeutics to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib in Combination with Camrelizumab in Unresectable Hepatocellular Carcinoma (uHCC)
Elevar Therapeutics FORT LEE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced it will host a virtual…
Comprehensive analysis of m6A regulators associated with immune infiltration in Hepatitis B virus-related hepatocellular carcinoma | BMC Gastroenterology
M6A regulators are likely to have a significant effect on HBV-related HCC Twenty m6A regulators, including 12 readers, 7 writers, and 1 eraser, were identified in the TCGA and GEO cohorts. The correlation network provided interactive information among the m6A regulators. The ratio of somatic mutations and CNV for the…
Phase 3 Findings Show PFS Benefit With Frontline Rivoceranib Plus Camrelizumab in Patients With Unresectable HCC
Patients with unresectable hepatocellular carcinoma (HCC) who received rivoceranib and camrelizumab achieved a statistically significant and clinically meaningful benefit in progression-free survival (PFS) and overall survival (OS) compared to those who received sorafenib (Nexavar), according to data from the phase 3 CARES 310 trial (NCT03764293) published in The Lancet.1,2 Findings showed that…
Phase 3 RATIONALE-301 Study Evaluates Tislelizumab vs Sorafenib in HCC
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the phase 3 RATIONALE-301 trial (NCT03412773) which evaluated frontline tislelizumab vs sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC). In the RATIONALE-301 trial, tislelizumab demonstrated improved health-related quality of life, physical functioning, fatigue, and HCC symptom…
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer | Antibodies
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer Details Category: Antibodies Published on Friday, 28 July 2023 17:17 Hits: 194 KEYTRUDA® (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus…
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
July 28, 2023 6:45 am ET KEYTRUDA® (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus chemotherapy KEYNOTE-756 is the first positive Phase 3 study with an immunotherapy regimen to demonstrate a statistically significant improvement in pCR rate in the neoadjuvant setting for this patient…
Single-molecule genome-wide mutation profiles of cell-free DNA for non-invasive detection of cancer
Genome-wide somatic mutation analyses of cancer tissues To develop this method, we examined whole-genome sequences of cancers from 2,511 individuals across 25 different cancers from the PCAWG study25,26, identifying distinct mutation frequencies across the genome in different tumor types (Extended Data Fig. 1). For example, analysis of lung tumor and…
First-Line Camrelizumab Plus Rivoceranib Outperforms Sorafenib in Unresectable HCC
Combination treatment with camrelizumab and rivoceranib is more effective than sorafenib monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC), according to research published in The Lancet. In this phase 3 trial, camrelizumab and rivoceranib prolonged progression-free survival (PFS) and overall survival (OS) when compared with sorafenib. However, the…
Rivoceranib/Camrelizumab is Effective in the First-Line for uHCC
In the phase 3 CARES 310 study (NCT03764293), the combination of rivoceranib, an oral tyrosine kinase inhibitor (TKI) and camrelizumab, a PD-1 inhibitor, produced a statistically significant and clinically meaningful benefit in progression-free survival (PFS) and overall survival (OS) vs sorafenib (Nexavar) for the first-line treatment of previously untreated patients…
Pan-cancer structurome reveals overrepresentation of beta sandwiches and underrepresentation of alpha helical domains
AlphaFold models significantly expanded structural space of over and underexpressed protein-coding genes in 21 cancer types Our non-redundant sets of over and underexpressed protein-coding genes for all cancer types include 5341 and 7320 genes, respectively. Figure 1A, B illustrates the availability of known 3D structures (PDB) and AlphaFold models (AF). For…
Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet
Elevar Therapeutics In CARES 310, camrelizumab plus rivoceranib demonstrated statistically significant and clinically meaningful prolonged overall survival and progression-free survival, and improved overall response rate versus sorafenib, a standard first-line treatment for uHCC FORT LEE, N.J., July 24, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB…
Microevolutionary processes analysis in the Lithuanian genome
Our analyses demonstrate that distinct microevolutionary scenarios can generate very similar and realistic biodiversity patterns (e.g., the latitudinal diversity gradient). One of the biggest hits that we saw of selection was found in a ~ 131 kb region in chromosome 6, when comparing Lithuanian groups with CEU and FIN populations, which comprise the…
CatalYm shows GDT-15 importance in immunotherapy resistance
CatalYm has published preclinical data in Nature Communications that reveal the central role of Growth Differentiation Factor-15 (GDF-15) in the resistance of tumors to current immunotherapy. The company said the findings further highlight the therapeutic significance of its proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies….
IJMS | Free Full-Text | DNA Methylation in the Fields of Prenatal Diagnosis and Early Detection of Cancers
1. DNA Methylation: Looking Back over the Century “Genes are equivalent to blueprints; epigenetics is the contractor. They change the assembly, the structure.” —Bruce Lipton. The methylation of the DNA is a quintessential epigenetic mechanism consisting of the binding of a methyl group to the fifth carbon of the cytosine…
Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer | Antibodies
Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer Details Category: Antibodies Published on Wednesday, 19 July 2023 18:10 Hits: 115 KEYTRUDA® (pembrolizumab) plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus…
FDA Accepts NDA for Rivoceranib/Camrelizumab in Unresectable HCC
Supporting data for the NDA came from the phase 3 CARES 310 study (NCT03764293), in which investigators assessed rivoceranib plus camrelizumab vs sorafenib among patients with unresectable HCC. The FDA has accepted a new drug application (NDA) for rivoceranib in combination with camrelizumab as a frontline treatment for patients with…
FDA Accepts NDA for Rivoceranib Plus Camrelizumab in Unresectable HCC
The phase 3 CARES 310 study (NCT03764293) previously evaluated rivoceranib (Apatinib) with camrelizumab (SHR-1210) in patients with unresectable hepatocellular carcinoma (uHCC) and support the FDA acceptance of the new drug application (NDA). In the study, the combination demonstrated statistically significant and clinically meaningful prolonged overall survival (OS) and progression-free survival…
Smad2 and Smad4 gene mutations in hepatocellular carcinoma
TGF-β is a negative regulator of liver growth. Smad family of genes, as mediators of TGF-β pathway, are candidate tumor suppressor genes in hepatocellular carcinoma (HCC). We studied 35 HCC and non-tumour liver tissues for possible mutations in Smad2 and Smad4 genes. Three tumours displayed somatic mutations; two in Smad4…
A prognostic four-gene signature and a therapeutic strategy for hepatocellular carcinoma: Construction and analysis of a circRNA-mediated competing endogenous RNA network
Background: Hepatocellular carcinoma (HCC) has a poor long-term prognosis. The competition of circular RNAs (circRNAs) with endogenous RNA is a novel tool for predicting HCC prognosis. Based on the alterations of circRNA regulatory networks, the analysis of gene modules related to HCC is feasible. Methods: Multiple expression datasets and RNA…
Presence of ribosomal gene / mitochondrial gene enrichment in each cluster of scRNA seq analysis
Presence of ribosomal gene / mitochondrial gene enrichment in each cluster of scRNA seq analysis 1 Hello Everyone, recently I have been working on the scRNA seq analysis of HBV-associated Heptatocellular carcinoma (HCC) cells using Seurat packages. When I used the 20 genes with lowest adjusted p-value in each cluster…
Can-Fite to Present at the Emerging Growth Conference on July 13, 2023
Can-Fite invites individual and institutional investors as well as analysts to attend its real-time, interactive presentation at the Emerging Growth Conference PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory, and liver diseases,…
Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas | Biomarker Research
Clinical data The demographic data of the 254 HCC patients are presented in Table S1. We found that treatment received by HCC patients were associated with patient survival, as shown in Fig. S1. Somatic mutations The mutational landscape is shown in Fig. 1. The top 10 most common mutated genes were…
the future of cfDNA testing?
Widely regarded as a founder of cell free DNA (cfDNA) technology, Professor Dennis Lo is now pioneering investigation into the emerging science of fragmentomics. If you were at were at our recent policy summit: making science work for health – from genomic foundations to policy futures you will have heard…
are we edging closer to a cure?
A viral infection that affects the liver and can cause both acute and chronic disease, hepatitis B affects around 296 million people worldwide, and, according to the latest statistics from the World Health Organization (WHO), it resulted in an estimated 820,000 deaths in 2019. The virus is most commonly transmitted…
Mitochondrial DNA is a target of HBV integration
Patients Tumour tissues from seven HBsAg-positive patients (6 men, 1 woman; mean age 66.7 ± 8 years) with HBV-related HCC and paired adjacent non-tumour tissues from six of them were studied. The clinical, histological, and virologic characteristics of the patients are summarised in Table 1. Two normal liver samples from HBV-negative patients who…
AstraZeneca’s liver cancer treatment shows ‘continued survival benefit’ in phase 3 trial
According to the study, the treatment demonstrated a sustained, clinically meaningful overall survival (OS) benefit at four years for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment. The updated results, which were presented at this year’s European Society…
AstraZeneca’s phase 3 liver cancer study shows continued survival benefit
AstraZeneca (AZ) has shared updated results from a late-stage study of its Imfinzi (durvalumab) plus Imjudo (tremelimumab) treatment plan in certain patients with hepatocellular carcinoma (HCC), the most common type of liver cancer. The dosing schedule of the combination is referred to as the STRIDE (single tremelimumab regular interval durvalumab)…
Circulating Cell-Free DNA as a Biomarker for Prognosis and Response to Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma
dataset posted on 2023-06-27, 10:46 authored by Watanabe T., Suzuki Y., Kuroda H., Hiraki H., Suzuki A., Tamura A., Ieko Y., Nishizuka S.S., Matsumoto T. Introduction: Systemic therapy provides clinical benefits to a subset of patients with advanced unresectable hepatocellular carcinoma (HCC). However, few biomarkers are available for predicting prognosis…
Phase 2 Evidence on Serplulimab Plus HLX04 in Advanced HCC Calls for Phase 3 Study
Image Credit: © SciePro [www.stock.adobe.com] Treatment with the dual PD-L1 and VEGF targeted therapy,serplulimab (HLX10) in combination with HLX04 demonstrated encouraging anti-tumor efficacy along with a favorable safety profile in patients with previously-treated advanced hepatocellular carcinoma (HCC).1 Findings come from a phase 2 study conducted in 41 Chinese patients with…
Transcriptomic Enrichment of Ferroptosis-Related Gene ACSL4 in Advanced Hepatic Fibrosis/Cirrhosis: Bioinformatics Analysis and Experimental validation
Abstract Background: Liver fibrosis is a critical part of the clinical process of liver disease that progresses to cirrhosis and even liver cancer, and effective treatment and clinical biomarkers are urgently needed to manage liver fibrosis. Ferroptosis, a notable biological phenomenon that has received attention because of the role it…
Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., June 20, 2023–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the Phase 3 KEYNOTE-585 trial, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as neoadjuvant treatment, followed by adjuvant treatment with KEYTRUDA plus chemotherapy, then KEYTRUDA…